摘要
目的研究多靶点叶酸拮抗剂培美曲塞治疗晚期非小细胞肺癌(NSCLC)的近期疗效和毒性反应。方法收集我院2008年1月至2010年1月资料完整的晚期非小细胞肺癌患者共18例,男10例,女8例,中位年龄51岁(范围32～68岁),均经组织学和/或细胞学证实,因化疗后出现复发或进展而采用培美曲塞化疗。化疗方案为培美曲塞500mg/m2单药或联合顺铂75mg/m2,每3周重复;对接受两个或两个以上化疗周期的患者进行化疗效果及副反应评价。结果 18例可评价疗效,无完全缓解(CR)病例,部分缓解(PR)仅2例,稳定者(SD)共12例,4例疾病进展(PD)。全组有效率(CR+PR)为11.1%(2/18),疾病控制率(DCR)为77.8%(14/18)。中位生存时间9.2个月,中位疾病进展时间2.8个月,1年生存率为31.2%。未出现化疗相关死亡,毒副反应主要为I～Ⅲ度胃肠道反应和骨髓抑制。结论培美曲塞治疗复治晚期NSCLC安全有效,耐受性良好。
Objective To evaluate the efficacy and toxicity of the multi-targeted antifolate pemetrexed in patients with advanced non-small cell lung cancer（NSCLC）.Methods Eighteen patients with advanced NSCLC were enrol1ed into the study from January 2008 to January 2010,which were diagnosed by histology and/or cytology,and had failed in previous chemotherapy.Among them 10 were male,8 were female,the median age was 51 years（ranging from 32 to 68 years）.The salvage chemotherapy strategy was single-agent pemetrexed 500 mg/m2 or pemetrexed 500 mg/m2 plus cisplatin 75 mg/m2（Pem Cis）.Pemetrexed was given on day 1 and cisplatin was given on day1~3 every 3 weeks.The patients who received chemotherapy two or more cyc1es were evaluated.Results There was no case with complete response,only 2 cases showed partial response,12 cases had stable disease and 4 cases got progressive disease.The responsive rate was 11.1%（2/18）,and the disease controlling rate was 77.8%（14/18）.The median survival time was 9.2 months,and the median time for progressive disease was 2.8 months with 1-year survival rate of 31.2%,there were no treatment-related deaths.The common side-effects were Grade Ⅰ/Ⅲ gastrointestinal response and hematologic toxicities.Conclusion Advanced or metastatic NSCLC patients previously treated could benefit from pemetrexed chemotherapy with tolerable adverse events.
出处
《临床肺科杂志》
2010年第11期1530-1532,共3页
Journal of Clinical Pulmonary Medicine
关键词
培美曲塞
顺铂
非小细胞肺癌
化疗
pemetrexed
cisplatin
non-small cell lung cancer（NSCLC）
chemotherapy
